Biologics News
CAMCEVI® (leuprolide) 42mg injection emulsion, FDA Approved for Treatment of Advanced Prostate Cancer, Available Exclusively at Biologics by McKesson
CARY, N.C., June 19, 2024—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
CARY, N.C., April 23, 2024 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was
FABHALTA (iptacopan), FDA Approved for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria, Available at Biologics by McKesson
CARY, N.C., Dec. 20, 2023 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was
OGSIVEO (nirogacestat) FDA Approved for Desmoid Tumors, Available at Biologics by McKesson
CARY, N.C., Dec.5, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks
TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec.1, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca
FRUZAQLA (fruquintinib), FDA Approved for the Treatment of Metastatic Colorectal Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 15, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by